Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipilou 10mg vs 20mg in High-risk Hypercholesterolemia
NCT04511000Phase 4Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of atorvastatin in hypercholesterolemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Mean Percent Change of Low-Density Lipoprotein Cholesterol at 12 weeks. Started Oct 2017; status: completed.
02
Drugs
atorvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04511000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511000.